There’s a ditch on both sides of the road, as the old saying goes, when it comes to antidepressants. While there is a large body of evidence validating their use to treat patients suffering from depression, a growing coalition of physicians and researchers is deeply worried about the overprescription of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), with usage in the U.S. climbing significantly in recent years, according to CDC data. This increase is often driven by off-label prescribing for conditions like anxiety or insomnia, rather than strictly for depression, critics argue. The trend raises questions about whether these medications are used appropriately, as their widespread application may expose patients to unnecessary risks without guaranteed benefits, especially when alternative treatments might suffice.
A 2023 study, for example, found that prenatal SSRI exposure can alter fetal brain development, with effects like reduced gray and white matter volume in children aged 7 to 15. These findings highlight the potential long-term implications of SSRI use and fuel debates over their overuse in pregnant women.
As with many drugs, the efficacy of antidepressants varies widely depending on the patient’s condition. For those with Major Depressive Disorder, all antidepressants were more efficacious than a placebo, according to a 2018 meta-analysis in The Lancet, making them a critical tool. However, for mild cases, therapy may outperform drugs. Despite this possibility, doctors may prescribe SSRIs due to patient expectations or limited access to alternatives, underscoring the need for better diagnostic tools and education to ensure prescriptions align with evidence-based need.
External pressures further complicate the balance between preventing overprescription and ensuring access for those who need antidepressants. Regulatory scrutiny and litigation create a chilling effect, making doctors hesitant to prescribe even when appropriate due to fear of legal repercussions. Meanwhile, alternative treatments remain underutilized due to high costs and lack of insurance coverage, pushing doctors toward cheaper, more accessible antidepressants despite their potential risks. Addressing these challenges requires a multifaceted approach, including wider access to non-drug therapies and better education for both patients and providers.
Share this article
Join GLP founder Jon Entine and longtime contributors Liza Dunn and Cameron English as they discuss the risks and benefits of antidepressants. Follow this link or listen to the conversation below:
— Liza Dunn (@DrLizaMD) May 30, 2025
